Definitive Contract 75N93019C00010
Award Date
5/31/19
Potential Completion Date
7/30/20
Potential Value
$288K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Plant Vax, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This is a $300,000.00 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Cure Systems LLC, a small disadvantaged business located in Newton, MA. The contract is for the development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies" and is related to NIAID's SBIR program objectives to stimulate technological...
This is a $1,500,000.00 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Department of Health and Human Services, to Cure Systems LLC, a self-certified small disadvantaged business located in Newton, Massachusetts. The contract is for the research and development of "Vector-Based Delivery of HIV Broadly Neutralizing Antibodies," a specialized approach to developing advanced...
The prime contractor Molecular Express Inc. was awarded a $300,000 firm fixed price Small Business Innovation Research Program Phase I contract by the National Institutes of Health National Institute of Allergy and Infectious Diseases. Under this contract, the contractor will engineer novel HIV GP41 ectodomain antigens for incorporation into VESIVAX immunogenic formulations, in response to a solicitation seeking proposals aligned with NIH and CDC public health missions. This total small business...
This federal contract award to Neovaxsyn Inc., a minority-owned small disadvantaged business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The $300,000 firm fixed-price contract supports the development of a next-generation immunoprevention platform against HIV-1, with a final completion date of October 31, 2025. The contract was awarded under the Small Business Innovation Research (SBIR) program, which...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...
This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Acousticabio, Inc., a small business in Cambridge, MA. The contract, valued at $295,116, is for the development of "HIGH-DOSE AND SUSTAINED DELIVERY OF HIV-1 BROADLY NEUTRALIZING ANTIBODIES VIA SUBCUTANEOUS INJECTION OF HYDROGEL-BASED MICROPARTICLE FORMATIONS". This contract is...
This is a $599,897 firm fixed price definitive contract between the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) and Pop Biotechnologies Inc., a Buffalo, NY-based biotechnology company. The objective of this Small Business Innovation Research (SBIR) Program Phase I contract is for Pop Biotechnologies to utilize a next-generation vaccine adjuvant to induce rapid and serum-stable spontaneous...